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Abstract: We demonstrate a method for imaging the wound healing process 
with  near  infrared  fluorescent  fibrinogen.  Wound  healing  studies  were 
performed on a rat punch biopsy model. Fibrinogen was conjugated with a 
near infrared fluorescent dye and injected into the tail vein. Fibrinogen is a 
useful protein for tracking wound healing because it is involved in fibrin 
clot  formation  and  formation  of  new  provisional  matrix  through 
transglutaminase’s crosslinking activity. Strong fluorescence specific to the 
wound  was  observed  and  persisted  for  several  days,  indicating  that  the 
fibrinogen  is  converted  to  crosslinked  fibrin.  Administration  of  contrast 
agent simultaneously with wound creation led to primary labeling of the 
fibrin  clot,  indicating  that  the  wound  was  in  its  early  phase  of  healing. 
Administration  on  the  following  day  showed  labeling  on  the  wound 
periphery, indicating location of formation of a new provisional matrix. This 
method  may  prove  to  be  useful  as  a  diagnostic  for  basic  studies  of  the 
wound healing process, in drug development, or in clinical assessment of 
chronic wounds. 
©2010 Optical Society of America 
OCIS  codes:  (170.2655)  Functional  monitoring  and  imaging;  (170.6935)  Tissue 
characterization;  (170.4580)  Optical  diagnostics  for  medicine;  (170.3880)  Medical  and 
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1. Introduction 
Wound healing is a dynamic and complex process involving several synchronized events that 
lead to blood clotting, healing of the wound site, and finally wound closure. Improper wound 
healing  can  lead  to  infection  and  severe  complications  that  can  lead  to  life-threatening 
conditions [1]. The healing cascade can be roughly divided into three overlapping phases: 
inflammation, proliferation, and tissue remodeling [2,3]. Tissue injury causes the leakage of 
blood  from  ruptured  blood  vessels  into  the  extravascular  space  and  induces  platelet 
aggregation.  Activated  platelets  promote  thrombin  formation  that  leads  to  fibrin  clot 
formation. The clot provides primary protection for the damaged tissue and also acts as a 
provisional  extracellular  matrix  (ECM).  The  coagulation  pathway  and  injured  cells  also 
release  various  signaling  mediators  and  chemotactic  factors  to  recruit  inflammatory 
leukocytes to the injury sites and initiate the healing process [4]. Once the wound is stabilized, 
re-epithelialization and proliferation processes start to form granulation tissue, replacing the 
fibrin clot and vascularizing the newly-growing tissue. The ECM in this phase is constantly 
degraded and reproduced to allow and support cell migration and tissue repair. During the 
remodeling phase, granulation tissue continues to be replaced and is transformed into scar 
tissue to reach the final resolution stage. 
Transglutaminases (TGs) are cross-linking enzymes that are involved in several phases of 
the  healing  process  [5,6].  The  primary  function  of  the  TGs  is  to  cross-link  its  substrates 
(various proteins and peptides) by catalyzing the formation of ε-(γ-glutamyl) lysine bonds 
(isopeptide  bonds)  between  amide  groups  of  glutamine  and  the  primary  amine  group  of 
various amines [7]. The resulting cross-linking products have higher resistance to chemical 
and  enzymatic  degradation  [8].  The  cross-linking  function  of  the  TGs  is  crucial  in  the 
formation of the provisional ECM during the healing process. TGs also serve as signaling 
molecules during the tissue repair process [9–11]. Many wound healing-related proteins have 
been identified as TG substrates (TGSub), such as fibrinogen, fibronectin, collagen, fibrin, 
and vitronectin [12,13]. At least two types of TGs are involved in the downstream coagulation 
cascade: thrombin-activated factor XIIIa, also called as plasma TG,  which cross-links  the 
fibrin monomers to form the fibrin clot; and tissue TG (TG2), which is expressed by epithelial 
cells around the wound site and is actively involved in the process of re-epithelialization and 
granulation  tissue  formation  [4].  Other  transglutaminases  that  can  play  a  role  include 
keratinocyte transglutaminase and epidermal transglutaminase. 
Due  to  the  complexity  and  diversity  of  wound  conditions,  current  clinical  wound 
assessment is typically performed through visual observation with or without the assistance of 
digital photography [14–16]. Dimensional and other qualitative information such as wound 
color, appearance, and location are collected for evaluating the healing progress. In general, 
these methods are somewhat subjective and the results are hard to quantify. In some cases, a 
histological examination that provides direct visualization of tissue is performed to assess if 
proper wound healing is occurring. However, histological examination involves sampling of 
the wound site, which in many cases can be difficult or even disruptive to already fragile 
tissue.  Several  groups  are  developing  in  vivo  imaging  techniques  to  monitor  the  wound 
healing  process  using  angiography  [17],  ultrasound,  optical  coherence  tomography  (OCT) 
[18–21] and photoacoustic microscopy [22]. These techniques provide reasonable structural 
resolution and most importantly give a chance to observe the newly formed tissue underneath 
the scab. However, the techniques mostly focus on the observation of re-epithelialization, re-
vascularization, and reformation of dermal-epidermal junction, events that are mainly related 
to late phases of the healing process, and do not provide the capability to identify specific 
biochemical defects in the healing process that would yield critical information to provide 
specific therapeutic intervention. TG has been shown to  have  multifunctional roles in the 
healing  process.  Mapping  TG  activity  in  the  wound  site  could  be  used  to  monitor  the 
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opportunity  to  distinguish  the  different  stages  of  wound  healing.  Optical  imaging  of  the 
TGSub  distribution  has  been  used  to  monitor  the  thrombosis  process  and  healing  after 
myocardial  infarction  [24,25].  Since  the  transglutaminases  are  also  associated  with  tumor 
boundaries [26,27], this approach is also of interest for cancer imaging. Here, we demonstrate 
the use of near infrared fluorescent dye-labeled fibrinogen (a transglutaminase substrate) as a 
contrast agent to monitor the progression of the wound healing in rat dermal tissues. 
2. Materials and methods 
Abbreviations used in this paper are listed in Table 1. 
Table 1. Abbreviations 
BSA  bovine serum albumin 
DMSO  dimethyl sulfoxide 
DTT  (2S,3S)-1,4-bis-sulfanylbutane-2,3-diol or dithiothreitol 
ECM  extracellular matrix 
EDTA  2,2',2”,2”'-(ethane-1,2-diyldinitrilo)tetraacetic acid 
hFg  human fibrinogen 
MW  molecular weight 
MWCO  molecular weight cut off 
NIR  near infrared 
OCT  optical coherence tomography 
SDS-PAGE  sodium dodecyl sulfate polyacrylamide gel electrophoresis 
TG  transglutaminase 
TG2  tissue transglutaminase 
TGSub  transglutaminase substrates 
VEGF  Vascular endothelial growth factor 
2.1 Materials 
Human fibrinogen (hFg) and bovine serum albumin (BSA) were obtained from Calbiochem. 
Near infrared (NIR) dye, HiLtye Fluor
TM 750 SE, was purchased from AnaSpec, Inc. All other 
chemicals were the highest grade available and used without further purification. 
2.2 Labeling Fibrinogen and BSA 
NIR  labels  were  prepared  following  the  suggested  protocol  provided  by  the  vendor 
(AnaSpec).  In  brief,  0.15−0.25  µmole  of  hFg  or  BSA  were  dissolved  in  100  mM 
Na2CO3/NaHCO3 pH 8.0 buffer. NIR dye (0.75−2.22 µmole) was first dissolved in 20  L 
DMSO and added to the buffer. The solution was kept at room temperature for 90−120 min. 
The  unlabeled  dye  was  then  removed  by  centrifugal  filtration  using  a  membrane  with  a 
molecular weight cut off (MWCO) of 30,000 (Millipore). The resulting labeled protein was 
reconstituted in normal saline at a concentration of 12  M (dye). The concentrations of dye 
and protein were determined by their absorbance at 754 and 280 nm, respectively. 
The ability of the labeled fibrinogen molecule to function as a TG substrate was tested by 
reacting with unlabeled hFg (viable TG substrate) in presence of guinea pig liver TG2 (N-
Zyme BioTec GmbH). Labeled hFg (13µg) and 4  g labeled BSA were reacted with 10  g 
unlabeled hFg in 150 mM NaCl, 5 mM DTT, 10 mM CaCl2, and 50 mM Tris buffer at pH 8.3. 
TG2  activity  is  calcium  dependent  and  should  produce  covalent  high  molecular  weight 
complexes that would not readily enter a SDS-PAGE gel. EDTA (10 mM) was used to inhibit 
TG2 activity as a negative control. BSA is not a TG substrate and should not form high 
molecular weight complexes. 
2.3 Imaging apparatus 
NIR animal images  were taken using a home-built imaging box as shown in Fig. 1. The 
camera was placed at top upright position and the excitation light sources were installed off-
axially and tilted to the center of view (tilt angle = 22.5°). Two high-power 735 nm LEDs 
(Epitex L735-66-60) were used as the excitation light source. LEDs were used because they 
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(Chroma  HQ710/75x)  were  used  to  cut  off  excitation  light  above  750  nm.  The  distances 
between LEDs and sample  were approximately 33 cm. An  Apogee  Alta-U6  monochrome 
CCD  digital  camera  was  used  to  acquire  images.  For  fluorescence  images,  a  Chroma 
HQ780LP filter and a Schott RG665 filter were used to eliminate scattered excitation light. 
For  the  “white  light”  images  (i.e.,  elastically  scattered  light  showing  the  illumination 
distribution on the animal), we used the same LED illumination and a neutral density filter 
(O.D. = 4) in front of the camera to avoid overexposure. A filter wheel (Optec IFW) was 
installed  to  exchange  the  filters.  The  system  was  controlled  by  LabVIEW
®.  Background 
(dark) images were acquired using opaque cardboard in one of the filter wheel positions. 
To acquire the images of dissected tissue with higher resolution, a scanning imager (LI-
COR Odyssey) was used with the spatial resolution set at 21  m. 
2.4 Imaging Protocol 
Fisher female rats (F344, 160–180 g, and 8−10 weeks old) were used for the animal imaging 
experiments. The rats were anesthetized during shaving, wound creation, and imaging using 
isoflurane inhalation (induction with 3-4% isoflurane for 30 seconds and maintenance with 1-
2% isoflurane, with oxygen as the balance gas). Four wounds were created in pairs on the 
upper dorsum using a sterile punch. The labels were administered through tail vein injection. 
The image resolution was set at 16 bits with 1 × 1 binning. For the fluorescence and 
background images, the exposure times were set at one second; for the “white light” images, 
the exposure was 0.2 second. The images were processed by MATLAB
® or ImageJ. 
 
Fig. 1. Schematic of imaging system. 
3. Results 
3.1 NIR labels 
The dye-to-protein (D/P) ratios of labels depend on the relative moles of NIR dye used in the 
conjugation reaction. The D/P ratio ranged from 1.2 to 4.4 for hFg labels and from 0.5 to 1.9 
for BSA. Considering that only a trace amount of fibrinogen and albumin was injected into 
the  rats,  the  difference  of  the  D/P  ratios  between  labels  is  not  significant.  However,  to 
facilitate quantitative comparison of the fluorescence emitted from each rat from different 
labels, the total amounts of conjugated dye injected into the animal were kept constant. The 
images presented here used D/P ratios of 2.9 for hFg and 1.9 for BSA. The total amount of 
injected conjugated dye was 3 nmole. 
To  identify  what  chains  of  fibrinogen  were  labeled  and  whether  labeling  altered 
crosslinking of fibrinogen, the labeled proteins were cross-linked with unlabeled hFg. SDS-
PAGE gels verified that the labeled proteins retained their TG2 activity as shown in Fig. 2. 
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(63.5 kDa), β (56 kDa), and γ (47 kDa) chains of fibrinogen were comparably labeled [28]. 
The intensities of these three bands were either significantly reduced or disappeared when 
guinea pig liver TG2 was activated (lanes 4 and 8) and several high molecular weight bands 
developed, indicating that cross-linking products were formed and may not have entered the 
SDS-PAGE gel. The NIR image (right panel) shows that the hFg label (lanes 3–5) exhibits the 
same pattern as  seen  with the Coomassie blue staining,  while the BSA  label shows  only 
limited  influence  from  the  presence  of  activated  TG2. Both  observations  suggest  that  the 
TGSub and control labels were labeled and reacted with TG2 as expected. 
3.2 Wound imaging 
The  LEDs  were  operated  at  an  output  of  550  mW  (per  LED).  The  net  output  after  the 
excitation filter was 80 mW (per LED). The rat was positioned so that the wound area would 
receive the maximum light distribution. The average power density at wound area was 0.7 
mW/cm
2. The inhomogeneity over the wound area was 3% and that across the whole rat body 
(not including the limbs and tail) was less than 22%. The HQ780LP filter has leakage up to 
59% from 380 to 520 nm. Although the imaging box was built as light-tight as possible and 
the room light was dimmed during the experiments, a RG665 filter was also placed in front of 
camera as a precaution against the potential exposure to visible light. The wound images were 
analyzed  without  further  normalization  for  light  input  but  corrected  by  subtracting  the 
background (dark) images acquired with the same exposure time. The image resolution was 
about 0.25 mm per pixel. To better monitor the overall performance and sensitivity of the 
imaging box, a small piece of paper with multiple coats from a purple marker was placed by 
the animal as an internal reference [the orange square at the right of the “NIR fluorescence” 
image in Fig. 3(a)]. The fluorescence intensity from this internal reference is recorded and 
calculated. The fluctuation for all images over the experimental period is less than 8%. 
The labels were injected via the tail vein. In case of excess bleeding before the label 
administration, the blood could quickly  form  fibrin gel  in absence of the label. The scab 
developed from label-free fibrin would block fluorescence. To avoid this complication, the 
wound creation only punched through the dermis layer and kept the underlying tissues intact. 
Figure  3  shows  the  NIR  fluorescence  images  of  the  punch  wounds.  The  labels  were 
administered within one hour after wound creation for all images in this figure. Using the hFg 
label as the contrast agent [Fig. 3(b)], the images show that the fluorescence contrast is strong 
and concentrated at the wounds. The contrast difference between wounded and normal tissues 
is substantial. For the BSA label [Fig. 3(c)], the images show that the contrast is medium to 
strong and dispersed over the upper dorsum. While one can still identify the wounds, the 
contrast difference between wounded and normal tissues is moderate on the images of first 48 
hours and much less significant for the rest. Time-lapse images acquired each day over the 
course of healing reveals that the strongest contrast of the hFg label is primarily associated 
with the scabs and can last over 3 days until the scabs fall off from the wounds, indicating that 
the hFg label is cross-linked into the fibrin by factor XIIIa or TG2. In contrast, the “Day 1” 
(24 hours after administration of the contrast agent) image for the BSA label shows that the 
contrast  distribution  is  in  dispersed  pattern  over  the  upper  dorsum  and  not  specifically 
associated with the wounds. The contrast is significantly reduced in the Day 2 images and 
thereafter.  This  dispersed  pattern  suggests  that  the  BSA  label  is  leaked  out  from  the 
circulation and temporarily deposited around the wounded tissue. The enhanced permeability 
of blood vessels was a hallmark of an acute inflammation response, which also takes place in 
the early phase of the wound healing. The significant reduction of the BSA label contrast 
within the central zone of fibrin formation indicates that the BSA label is not preferentially 
immobilized at the wound site by blood coagulation due to its lack of reactivity with fibrin 
and TGs. 
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Fig.  2.  SDS-PAGE  gel  images  showing  Coomassie  blue  staining  (left  panel)  and  NIR 
fluorescence (right panel) for the same gel. Lanes 1 and 6 are protein MW standards. Lane 2 is 
unlabeled hFg only. Three major bands (from top to bottom) represent α (63.5 kDa), β (56 
kDa), and γ (47 kDa) chains, respectively. Lanes 3–5 and 7–9 are protein with NIR labels (3–5: 
hFG and 7–9: BSA) Lanes 3 and 7 have no TG2. Lanes 4 and 8 are incubated with TG2. Lanes 
5 and 9 are incubated with both TG2 and EDTA. EDTA inhibits the cross-linking reaction of 
TG2. 
Quantitative analysis of the same data set [Fig. 4(a), solid lines] shows similar trends to 
the  direct  observations  of  Fig.  3.  Administration  of  the  hFg  label  24  hours  after  wound 
creation  [dashed  lines  in  Fig.  4(a)]  produces  fluorescence  intensity  decays  that  are  quite 
similar to those with label administration on the same day as wound creation [solid lines in 
Fig. 4(a)]. This documents that fibrin formation and stabilization by TGs can continue after 
the  fibrin  clot  appears  to  have  formed  an  adequate  barrier  to  blood  loss.  A  recent  study 
monitoring TG expression in a punch biopsy model in rats also shows a strong increase in TG 
expression between the day of the wound and the 24-72 hrs after the wound administration 
[29]  The  distribution  of  hFg  label  one  day  after  wounding  may  be  a  combination  of 
crosslinking and continued formation and degradation of fibrin at the site of tissue injury. For 
the BSA label, comparing the “Day 1” image for BSA label injection within one hour after 
wound creation [Fig. 3(c)] with the “Day 1” image for BSA label injection 24 hours after 
wound creation [Fig. 4(c)] shows that the later injection produces much less contrast from the 
tissue beneath the wounds, indicating that there is a reduced inflammation reaction around the 
wound sites after 24 hours. 
3.3 Monitoring the progression of wound healing 
The progression of wound healing strongly depends on the depth, size, position, and cause of 
the wound, as well as the physiological condition of the animal or individual. Considering the 
scope of this study, the dermal wound created by punch biopsy was adopted as the wound 
model  to  avoid  excess  bleeding,  severe  infection,  and  possible  complications  due  to  the 
wound  creation  in  deep  tissues.  However,  to  examine  the  potential  use  of  hFG  label  for 
tracking the progression of wound healing, hFG label  was administrated at different  time 
points  after  wound  creation  and  the  distribution  patterns  of  the  hFG  label  were  carefully 
compared. 
The early phase of the healing process involves hemostasis over the wound site, which 
provides protection for the damaged tissue and prevents further injury. Plasma TG (Factor 
XIIIa) plays a significant role in this step by cross-linking TG substrates to form the initial 
ECM. In the presence of dye-labeled TG substrate at this stage, the label should deposit over 
the wound sites as part of fibrin clot. The “Day 2” image collected from administering the hFg 
label within one hour after wound creation shows an even brightness at the center and edge of 
wound [Fig. 5(a)], consistent with this pattern. After the acute inflammatory response, the 
healing process starts to advance to the proliferation phase. In this phase, epithelial cells start 
to express TG2 to initialize the re-epithelialization process. The “Day 2” image from the hFg 
label administered 24 hours after wound creation [Fig. 5(b)] shows a stronger contrast at the 
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Fig. 3. Wound images. (a) Typical “white light” and NIR fluorescence images. The images in 
(b) and (c) are the expanded time-lapse images of wound sites, showing hFg label and BSA 
label respectively. The Day 0 image was taken within 5 min of contrast injection. Day 1 was 
taken 24 hrs after injection, Day 2, 48 hours after injection, and so forth. 
Figure 5(c) shows an image acquired with the Odyssey
® of a 10  m-thick tissue section 
harvested from the rat administered with the hFg label 24 hours after wound creation at the 
time point of “Day 2” [48 hours after the injection, the same conditions as Fig. 5(b)]. The 
green is from the 800 nm channel and the red is from the 700 nm channel, representing NIR 
fluorescence and auto-fluorescence, respectively. The hFg label (green) is deposited around 
the wound, indicating high TG activity at that region which is consistent with the observation 
using the macro imaging system [Fig. 5(b)]. The width of hFg labeled ring is estimated about 
1 mm. 
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Fig. 4. (a) Plot of fluorescence intensity vs. time. The intensities were integrated from the 
wound  individually.  8-12  wounds  were  inspected.  The  error  bars  describe  the  standard 
deviations  of  the  intensity  distribution.  Solid  lines  represent  the  fluorescence  changes  for 
administration of the labels 1 hr after wound creation. Dashed lines are for administration of 
the labels 24 hrs after wound creation. Black and red: hFg. Blue and green: BSA. (b) and (c) 
are “Day 1” image (24 hrs after label administration) of the wound, for which the labels were 
injected into rat 24 hrs after wound creation. (b) is for hFg label. (c) is for BSA label. 
 
Fig. 5. “Day 2” images of wounds taken from giving hFg labels within 1hr (a) and 24 hrs (b) 
after wounding. (c) Tissue section of wound site. 
4. Discussion and Conclusions 
The wound healing process involves numerous signaling molecules, factors and mechanisms, 
which are also associated with a wide range of disease states. An unhealed wound or wound 
with prolonged  healing  time often indicates  that  there are serious  health concerns  for the 
patient.  It  is  well  known  that  wound  healing  is  impaired  in  a  diabetic  foot  ulcer. 
Approximately 90% of all low-extremity amputations happen in diabetic patients whose leg 
wounds  failed  to  heal.  Bedsores,  or  pressure  ulcers,  are  developed  in  patients  who  are 
immobile or confined to beds because of disease or trauma. The prolonged healing time of 
these ulcers may progress to severe systemic infections. Under these situations and others, 
precise  monitoring  of  the  wound  healing  process  would  give  valuable  information  for 
effective treatment. There are currently no methods that can provide a dynamic image of the 
process of fibrin formation and stabilization at sites of wound healing. 
Molecular imaging uses the contrast agent to target specifically a particular biological 
pathway, and gives an image that contains not only the structural information but also the 
functional status of the process. In this study we perform conventional fluorescence imaging, 
which is both simple and sensitive. However, there are other imaging modes that provide 
additional information such as depth resolution or structural information at the expense of 
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fluorescence-guided optical coherence tomography uses fluorescence molecular imaging as 
the  guide  to  obtain  high  resolution  OCT  images  [30].  Another  example  is  functional 
photoacoustic imaging [31–34], which benefits from molecular functionality and resolution of 
the image depth. Two photon microscopy provides optical sectioning through the nonlinear 
response with focal intensity, and can so also provide depth resolution. Here, we demonstrated 
use of NIR fluorescent hFg labels as contrast agents to monitor the wound healing process. 
We found that the fibrin formation and stabilization process is a dynamic event that continues 
for  up  to  24  hours  after  blood  loss  has  stopped.  Furthermore,  the  tissue  surrounding  the 
primary hemostatic fibrin clot remains permeable and deposits additional fibrin, it is currently 
unknown whether a wound that fails to heal continues to produce local fibrin and/or has a 
defect  in  depositing  fibrin  in  the  surrounding  tissue  to  promote  wound  healing.  Vascular 
endothelial  growth  factor  (VEGF),  a  molecule  that  promotes  cell  migration  and  vascular 
permeability early during would healing, is reported to be defective in diabetic wounds [35]. 
VEGF expression could be used as a molecular marker to assess the permeability changes 
during wound healing [36]. The use of this technique could further define whether wounds in 
diabetes form stable clots or have fibrin clots that fail to deposit fibrin in the adjacent tissue. 
For  injection  on  the  day  of  the  wound,  the  labeled  fibrinogen  deposits  in  the  wound 
because thrombin generated at the site of blood clotting converts the soluble fibrinogen to a 
fibrin  gel.  The  fibrin  becomes  stable  by  the  crosslinking  action  of  factor  XIIIa.  When 
fibrinogen is injected after the clot forms it is very likely that it gets cross-linked into the 
matrix by the enzymatic action of transglutaminases that are in the tissue, as supported by the 
patterns of hFg labeling [Figs. 5(b) and 5(c)] and previous studies using immunohistochemical 
staining [29]. Fibrin is a complex network of fibrin fibers that localizes where thrombin is 
generated and converts soluble fibrinogen to polymerizing fibrin molecules. Fibrin molecules 
polymerize end-to-end and side-by-side producing a highly concentrated network of fibrin 
molecules that would be highly fluorescent. Compared with the other enzymatic mechanisms 
of contrast formation, fibrin polymerization and a cross-linking mechanism that localizes and 
makes the molecule resistant to degradation would generate a stronger and more persistent 
contrast. The trade-off for this mechanism is the speed of contrast formation. The circulation 
time of TGSub labels may also be varied to optimize this imaging strategy. The longer the 
circulation time, the stronger the resulting contrast. However, if the circulation time of the 
TGSub label were too long, it would be less useful for monitoring fast-paced wound healing 
processes.  As  aforementioned,  at  different  phases  of  wound  healing  process,  different 
subtypes of TG are involved. It would be very beneficial to develop TGSub labels which 
selectively target at certain subtype of TGs. Hitomi et al. have developed two phage-displayed 
peptide libraries of TG substrates that show strong in vitro selectivity to factor XIIIa and TG2, 
respectively [37]. We are currently developing peptide-based TGSub labels with optimized 
circulation times and selectivity to different TG subtypes to address these opportunities. 
Acknowledgement 
This  work  was  supported  by  the  DOD  Breast  Cancer  Research  Program,  Grant  Number 
W81XWH-05-1-0386, and the National Cancer Institute, Grant Number 1R21 CA107285. 
#130226 - $15.00 USD Received 16 Jun 2010; revised 19 Jul 2010; accepted 19 Jul 2010; published 27 Jul 2010
(C) 2010 OSA 2 August 2010 / Vol. 1,  No. 1 / BIOMEDICAL OPTICS EXPRESS  294